Mavorixafor: A spotlight on the clinical aspects and prospects of the first USFDA-approved treatment for the primary immunodeficiency WHIM syndrome

Mohd Imran, Abdulaziz Khalaf Alshammari, Khalid Ramadan Alhamad, Majd Ahmed Alghamdi, Maryam Adnan Alghareeb, Renad Adnan Alghareeb, Omar Ibrahim Aldhafiri, Jumanah Basem Al-Humud, Syed Mohammed Basheeruddin Asdaq, Abida .

Abstract


WHIM syndrome (WHIMS) is an extremely rare, severe, and potentially fatal genetic condition that affects the immune system, leading to warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM). Effective therapy for WHIMS requires regular monitoring, medical intervention, and a collaborative approach to treatment. Due to the limited therapeutic options, addressing WHIMS is an unmet medical need. The United States Food and Drug Administration (USFDA) recently granted approval for mavorixafor as the first treatment for WHIMS. This review focuses on the pharmacological characteristics, clinical investigations, associated inventions, and prospects of mavorixafor. The literature for this article was searched on PubMed, reputable websites (USFDA and X4 Pharmaceuticals) and free patent databases like Espacenet. WHIMS is distinguished by severe neutropenia and hypogammaglobulinemia, which increases the risk of developing cancer. Mavorixafor enhances the movement of neutrophils and lymphocytes from the bone marrow (BM) to the bloodstream. Hence, it could be beneficial for managing medical illnesses characterized by a decrease in the quantity of neutrophils and lymphocytes in the bloodstream. X4 Pharmaceuticals has submitted patent applications for the utilization of mavorixafor in the treatment of diverse cancer types, inflammatory ailments, B-cell dysfunction, Waldenstrom's macroglobulinemia, and primary immunodeficiency disorders. This suggests that mavorixafor can effectively treat various disorders either alone or when used in conjunction with other medications. It will be intriguing to observe the future approvals of mavorixafor for various disorders.

Keywords: Mavorixafor; WHIM syndrome; Cancer; Immunodeficiency; Patent; Prospect   


Full Text:

PDF

References


Heusinkveld LE, Majumdar S, Gao JL, McDermott DH, Murphy PM. WHIM Syndrome: from pathogenesis towards personalized medicine and cure. Journal of Clinical Immunology, (2019); 39(6): 532-556.

McDermott DH, Murphy PM. WHIM syndrome: Immunopathogenesis, treatment and cure strategies. Immunological reviews, (2019); 287(1): 91-102.

Majumdar S, Murphy PM. Adaptive immunodeficiency in WHIM syndrome. International Journal of Molecular Sciences, (2018); 20(1): 3.

Janssens R, Struyf S, Proost P. Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Reviews, (2018); 44: 51-68.

Rodríguez-Frade JM, González-Granado LI, Santiago CA, Mellado M. The complex nature of CXCR4 mutations in WHIM syndrome. Frontiers in Immunology, (2024); 15: 1406532.

Zmajkovicova K, Nykamp K, Blair G, Yilmaz M, Walter JE. Expanding CXCR4 variant landscape in WHIM syndrome: integrating clinical and functional data for variant interpretation. Frontiers in Immunology, (2024); 15: 1411141.

Yilmaz M, Potts DE, Geier C, Walter JE. Can we identify WHIM in infancy? Opportunities with the public newborn screening process. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, (2022); 190(2): 215-221.

Hoy SM. Mavorixafor: First Approval. Drugs, (2024); 84(8): 969-975.

Geier CB. Mavorixafor: a new hope for WHIM syndrome. Blood, (2024); 144(1): 1-2.

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm (Accessed on June 30, 2024).

Center For Drug Evaluation and Research. Product Quality Review(s). Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218709Orig1s000ChemR.pdf (Accessed on June 30, 2024).

Center For Drug Evaluation and Research. Labeling. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218709Orig1s000Lbl.pdf (Accessed on June 30, 2024).

National Library of Medicine (U.S.). Clinical trial studies. Available at https://clinicaltrials.gov/ (Accessed on July 25, 2024).

Center For Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review(s). Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218709Orig1s000RiskR.pdf (Accessed on June 30, 2024).

Center For Drug Evaluation and Research. Integrated review. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218709Orig1s000IntegratedR.pdf (Accessed on June 30, 2024).

Center For Drug Evaluation and Research. Other Review(s) Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218709Orig1s000OtherR.pdf (Accessed on June 30, 2024).

Andtbacka RHI, Wang Y, Pierce RH, Campbell JS, Yushak M, et al. Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma. Cancer Research Communications, (2022); 2(8): 904-913.

Choueiri TK, Atkins MB, Rose TL, Alter RS, Ju Y, et al. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investigational New Drugs, (2021); 39(4): 1019-1027.

Dale DC, Firkin F, Bolyard AA, Kelley M, Makaryan V, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood, (2020); 136(26): 2994-3003.

Badolato R, Alsina L, Azar A, Bertrand Y, Bolyard AA, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood, (2024); 144(1): 35-45.

Dale DC, Firkin F, Bolyard AA, Kellay M, Makaryan V, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood, (2020); 136(26): 2994-3003.

Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, et al. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochemical pharmacology, (2012); 83(4): 472-479.

Hudu SA, Elmigdadi F, Qtaitat AA, Almehmadi M, Alsaiari AA, et al. Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need. Journal of Clinical Medicine, (2023); 12(15): 5114.

Hudu SA, Alshrari AS, Al Qtaitat A, Imran M. VP37 protein inhibitors for Mpox treatment: Highlights on recent advances, patent literature, and future directions. Biomedicines, (2023); 11(4): 1106.

Alshrari AS, Hudu SA, Elmigdadi F, Imran M. The urgent threat of Clostridioides difficile infection: A glimpse of the drugs of the future, with related patents and prospects. Biomedicines, (2023); 11(2): 426.

Brands KMJ. Compositions of CXCR4 inhibitors and methods of preparation and use. United States Patent Number US10548889B1, (2020). Available at https://patents.google.com/patent/US10548889B1/en?oq=US10548889B1.

Arbeit RD, Ragan PM. Methods for treating immunodeficiency disease. United States Patent Number US10610527B2, (2020). Available at https://patents.google.com/patent/US10610527B2/en?oq=US10610527B2.

Ragan PM, Arbeit RD, Crowley KJ. Methods for treating cancer. United States Patent Number US10953003B2, (2021). Available at https://patents.google.com/patent/US10953003B2/en?oq=+US10953003B2.

Brands KM. Compositions of CXCR4 inhibitors and methods of preparation and use. United States Patent Number US11045461B2, (2021). Available at https://patents.google.com/patent/US11045461B2/en?oq=+US11045461B2.

Arbeit RD, Ragan PM. Methods for treating immunodeficiency disease. United States Patent Number US11219621B2, (2022). Available at https://patents.google.com/patent/US11219621B2/en?oq=+US11219621B2.

Arbeit RD, Ragan PM, Atkins MB, Mier JW, Mcdermott D. Methods for treating cancer. United States Patent Number US11357742B2, (2022). Available at https://patents.google.com/patent/US11357742B2/en?oq=+US11357742B2.

Nguyen C, Taveras A. Treatments for conditions involving increased IL-6 levels. PCT Patent Application Publication Number WO2023240259A1, (2023). Available at https://patents.google.com/patent/WO2023240259A1/en?oq=+WO2023240259A1.

Nguyen C, Taveras A. Combination therapies for treating hyperproliferative disorders. PCT Patent Application Publication Number WO2023240258A1, (2023). Available at https://patents.google.com/patent/WO2023240258A1/en?oq=+WO2023240258A1.

Nguyen C, Taveras A. Treatments for single-mutant waldenström's macroglobulinemia. PCT Patent Application Publication Number WO2023172640A1, (2023). Available at https://patents.google.com/patent/WO2023172640A1/en?oq=+WO2023172640A1.

Taveras A, Zmajkovicova K, Nguyen C. Methods for treating primary immunodeficiency. PCT Patent Application Publication Number WO2023107689A1, (2023). Available at https://patents.google.com/patent/WO2023107689A1/en?oq=+WO2023107689A1.

Kelley EL, Cohen S. Methods for treating neutropenia. United States Patent Application Publication Number US2023014231A1, (2023). Available at https://patents.google.com/patent/US20230014231A1/en?oq=+US2023014231A1.

Johnson VA, Cramer YS, Rosenkranz SL, Becker S, Klingman KL, et al. Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210. AIDS Research and Human Retroviruses, (2019); 35(8): 691-697.

Tripathi R, Kumar P. Preliminary study to identify CXCR4 inhibitors as potential therapeutic agents for Alzheimer's and Parkinson's diseases. Integrative Biology (Camb), (2023); 15: zyad012.

Miao M, De Clercq E, Li G. Clinical significance of chemokine receptor antagonists. Expert Opinion on Drug Metabolism & Toxicology, (2020); 16(1): 11-30.

Uchida D, Kuribayashi N, Kinouchi M, Sawatani Y, Shimura M, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncology Reports, (2018); 40(1): 303-308.

Hanselmann R, Brands KMJ. Synthesis of mavorixafor and intermediates thereof. PCT Patent Application Publication Number WO2023059903A1, (2023). Available at https://patents.google.com/patent/WO2023059903A1/en?oq=WO2023059903A1

Hines D, Hines R. Methods of treating 5HT2a receptor-mediated conditions. PCT Patent Application Publication Number WO2023212244A1, (2023). Available at https://patents.google.com/patent/WO2023212244A1/en?oq=WO2023212244A1

Arkin I, Singh TPP, Krugliak M. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents. United States Patent Application Publication Number US2023190769A1, (2023). Available at https://patents.google.com/patent/US20230190769A1/en?oq=US2023190769A1

Zhang Y, Liu D, He H, Ma M, Wang J. Double-targeting tumor microenvironment response multifunctional nano delivery system and preparation method and application thereof. Chinese Patent Number CN115252790B, (2024). Available at https://patents.google.com/patent/CN115252790B/en?oq=CN115252790B

Imran M, Khan SA, Abida, Alshrari AS, Eltahir Mudawi MM, et al. Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021. Expert Opinion on Therapeutic Patents, (2022); 32(5): 591-604.

Imran M, Khan SA, Alshammari MK, Alqahtani AM, Alanazi TA, et al. Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis. Pharmaceuticals (Basel), (2022); 15(2): 128.

Imran M, Alshrari AS, Thabet HK, Abida, Afroz Bakht M. Synthetic molecules as DprE1 inhibitors: A patent review. Expert Opinion on Therapeutic Patents, (2021); 31(8): 759-772.

Nyunt MM, Becker S, MacFarland RT, Chee P, Scarborough R, et al. Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. Journal of Acquired Immune Deficiency Syndromes, (2008); 47(5): 559-565.

Cao YJ, Flexner CW, Dunaway S, Park JG, Klingman K, et al. Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrobial Agents and Chemotherapy, (2008); 52(5): 1630-1634.




DOI: http://dx.doi.org/10.62940/als.v11i4.3504

Refbacks

  • There are currently no refbacks.